You are here:
26 May 2021 / deal

Gilde Healthcare's Private Equity fund sells majority stake in European CRO/CDMO Symeres to Keensight Capital

Keensight Capital, one of the principal private equity managers dedicated to pan-European Growth Buyout1 investments, has reached an agreement to invest alongside management in Symeres, a leading European drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO).

Gilde Healthcare's Private Equity fund sells majority stake in European CRO/CDMO Symeres to Keensight Capital

According to the terms of the agreement, Keensight Capital will acquire a majority stake in Symeres from the Gilde Healthcare Private Equity fund, a leading European specialist healthcare investor.



Yucaipa Acquisition Corporation on USD 3.2 billion deSPAC merger with SIGNA Sports United

YAC on USD 3.2 billion deSPAC merger with SIGNA Sports United

The combination also includes the acquisition of the WiggleCRC Group, currently owned by Bridgepoint. read more
Voogd & Voogd group and Heilbron group merged

Voogd & Voogd group and Heilbron group merged

The merger creates a new group with a solid, ambitious and dynamic market position between Dutch and international players. read more
Genoteerd - Spoedprocedures in overnameprocessen

Quoted - Expedited proceedings in takeover processes

The relevant differences between inquiry proceedings and summary proceedings as a means of initiating expedited proceedings in takeover processes. read more